Study #2023-0660
A phase II study of the Menin inhibitor Revumenib in leukemia associated with upregulation of HOX genes
MD Anderson Study Status
Enrolling
Treatment Agent
Revumenib
Description
To learn if revumenib (also known as SNDX-5613) can help to control leukemias associated with an increase in expression of HOX genes.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Leukemia, HOX Gene
Study phase:
Phase II
Physician name:
Ghayas Issa
Department:
Leukemia
For general questions about clinical trials:
1-866-599-0508
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.